{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:09:07Z","timestamp":1792804147244,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018217","name":"Universidade Federal De S\u00e3o Paulo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018217","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Brain Res"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>L-DOPA (LD) is the gold-standard treatment of motor symptoms in Parkinson\u2019s disease (PD), conventionally used to prove the predictive value of PD animal models. This study aimed to investigate the predictive validity of an adaptation of the conventional reserpine model of PD: the repeated low-dose reserpine administration in rodents, which promotes progressive motor impairment in catalepsy, vacuous chewing behavior tests, and neurochemical deficits. Specifically, we investigated the effects of acute and chronic treatment with LD on motor alterations induced in mice by this modified protocol. Swiss mice were treated with 20 reserpine injections (0.1\u00a0mg\/kg, s.c., every other day). Acute LD (25, 50, 100, and 200\u00a0mg\/kg) administration was performed at the end of reserpine protocol to assess immediate motor recovery. Additionally, concomitant chronic LD (50 and 100\u00a0mg\/kg) treatment was conducted to investigate potential attenuation of motor impairment and dopamine depletion quantified by HPLC. Repeated reserpine protocol induced motor deficits in catalepsy and vacuous chewing evaluations and striatal dopamine depletion. Acute LD administration significantly improved catalepsy in higher doses, while chronic LD treatment attenuated motor impairments and reduced dopamine depletion in the striatum. These findings support the predictive validity of the reserpine rodent model for studying parkinsonism. Together with the ability to promote chronic and progressive parkinsonian alterations, the reversion of these deficits by LD reinforces the potential of the repeated low-dose reserpine protocol for studies of potential therapies and the pathophysiology underlying neurodegenerative processes in PD.<\/jats:p>","DOI":"10.1007\/s00221-026-07316-8","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T11:32:30Z","timestamp":1778499150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive validation of the repeated low-dose reserpine rodent model of parkinsonism"],"prefix":"10.1007","volume":"244","author":[{"given":"Vinicius","family":"Bioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro C.","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora M. G.","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narriman","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo B.","family":"Lopes-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o P.","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela B. L.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"Becegato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline C.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anderson H. F. F.","family":"Le\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina H.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"4","key":"7316_CR1","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00213-002-1081-7","volume":"161","author":"VC Abilio","year":"2002","unstructured":"Abilio VC, Vera JA Jr, Ferreira LS, Duarte CR, Carvalho RC, Grassl C et al (2002) Effects of melatonin on orofacial movements in rats. Psychopharmacology 161(4):340\u2013347. https:\/\/doi.org\/10.1007\/s00213-002-1081-7","journal-title":"Psychopharmacology"},{"issue":"1","key":"7316_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/s0278-5846(02)00340-8","volume":"27","author":"VC Abilio","year":"2003","unstructured":"Abilio VC, Araujo CC, Bergamo M, Calvente PR, D\u2019Almeida V, Ribeiro RA et al (2003) Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione\/reduced glutathione ratio (GSSG\/GSH) enhancement in rats. Prog Neuropsychopharmacol Biol Psychiatry 27(1):109\u2013114. https:\/\/doi.org\/10.1016\/s0278-5846(02)00340-8","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"7316_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuropharm.2004.04.003","volume":"47","author":"VC Abilio","year":"2004","unstructured":"Abilio VC, Silva RH, Carvalho RC, Grassl C, Calzavara MB, Registro S et al (2004) Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia. Neuropharmacology 47(2):263\u2013272. https:\/\/doi.org\/10.1016\/j.neuropharm.2004.04.003","journal-title":"Neuropharmacology"},{"key":"7316_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084323","author":"L Agnello","year":"2024","unstructured":"Agnello L, Gambino CM, Ciaccio AM, Masucci A, Vassallo R, Tamburello M et al (2024) Molecular biomarkers of neurodegenerative disorders: a practical guide to their appropriate use and interpretation in clinical practice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25084323","journal-title":"Int J Mol Sci"},{"key":"7316_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-025-00856-1","author":"A Antonini","year":"2025","unstructured":"Antonini A, Bergmans B, Kern DS, Gandor F, Nishikawa N, Standaert DG et al (2025) Foslevodopa\/Foscarbidopa in younger patients earlier within advanced Parkinson\u2019s disease: post hoc analysis of a randomized trial. Neurol Ther. https:\/\/doi.org\/10.1007\/s40120-025-00856-1","journal-title":"Neurol Ther"},{"key":"7316_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.neuroscience.2025.08.041","volume":"584","author":"D Atanasovski","year":"2025","unstructured":"Atanasovski D, Bergquist F, Eriksson E, Carlsson T (2025) The dopamine stabilizer (-)-OSU6162 attenuates levodopa-induced dyskinesia in the unilateral 6-hydroxydopamine rat model of Parkinson\u2019s disease. Neuroscience 584:404\u2013411. https:\/\/doi.org\/10.1016\/j.neuroscience.2025.08.041","journal-title":"Neuroscience"},{"key":"7316_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052298","author":"G Barriere","year":"2025","unstructured":"Barriere G, Pelloquin-Mvogo Z, Boulain M, Khsime I, Bharatiya R, Riquier MA et al (2025) Widespread and heterologous effects of L-DOPA on monoaminergic tissue metabolism in newborn rats expressing air-stepping. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26052298","journal-title":"Int J Mol Sci"},{"issue":"5","key":"7316_CR8","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/mds.24985","volume":"27","author":"D Berg","year":"2012","unstructured":"Berg D, Marek K, Ross GW, Poewe W (2012) Defining at-risk populations for Parkinson\u2019s disease: lessons from ongoing studies. Mov Disord 27(5):656\u2013665. https:\/\/doi.org\/10.1002\/mds.24985","journal-title":"Mov Disord"},{"key":"7316_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.fct.2018.11.056","volume":"124","author":"JIA Beserra-Filho","year":"2019","unstructured":"Beserra-Filho JIA, de Macedo AM, Leao A, Bispo JMM, Santos JR, de Oliveira-Melo AJ et al (2019) Eplingiella fruticosa leaf essential oil complexed with \u03b2-cyclodextrin produces a superior neuroprotective and behavioral profile in a mice model of Parkinson\u2019s disease. Food Chem Toxicol 124:17\u201329. https:\/\/doi.org\/10.1016\/j.fct.2018.11.056","journal-title":"Food Chem Toxicol"},{"issue":"7","key":"7316_CR10","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s11011-022-01032-2","volume":"37","author":"JIA Beserra-Filho","year":"2022","unstructured":"Beserra-Filho JIA, Maria-Macedo A, Silva-Martins S, Custodio-Silva AC, Soares-Silva B, Silva SP et al (2022) Lippia grata essential oil complexed with \u03b2-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism. Metab Brain Dis 37(7):2331\u20132347. https:\/\/doi.org\/10.1007\/s11011-022-01032-2","journal-title":"Metab Brain Dis"},{"key":"7316_CR11","doi-asserted-by":"publisher","first-page":"8429290","DOI":"10.1155\/2017\/8429290","volume":"2017","author":"LEM Brandao","year":"2017","unstructured":"Brandao LEM, Noga D, Dierschnabel AL, Campelo C, Meurer Y, Lima RH et al (2017) Passiflora cincinnata extract delays the development of motor signs and prevents dopaminergic loss in a mice model of Parkinson\u2019s disease. Evid Based Complement Alternat Med 2017:8429290. https:\/\/doi.org\/10.1155\/2017\/8429290","journal-title":"Evid Based Complement Alternat Med"},{"key":"7316_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.bbr.2017.04.028","volume":"328","author":"CLC Campelo","year":"2017","unstructured":"Campelo CLC, Santos JR, Silva AF, Dierschnabel AL, Pontes A, Cavalcante JS et al (2017) Exposure to an enriched environment facilitates motor recovery and prevents short-term memory impairment and reduction of striatal BDNF in a progressive pharmacological model of parkinsonism in mice. Behav Brain Res 328:138\u2013148. https:\/\/doi.org\/10.1016\/j.bbr.2017.04.028","journal-title":"Behav Brain Res"},{"issue":"3","key":"7316_CR13","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00213-002-1247-3","volume":"165","author":"BB Carlson","year":"2003","unstructured":"Carlson BB, Wisniecki A, Salamone JD (2003) Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor. Psychopharmacology 165(3):229\u2013237. https:\/\/doi.org\/10.1007\/s00213-002-1247-3","journal-title":"Psychopharmacology"},{"issue":"4596","key":"7316_CR14","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/1801200a0","volume":"180","author":"A Carlsson","year":"1957","unstructured":"Carlsson A, Lindqvist M, Magnusson T (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180(4596):1200. https:\/\/doi.org\/10.1038\/1801200a0","journal-title":"Nature"},{"key":"7316_CR15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fneur.2014.00078","volume":"5","author":"M Carta","year":"2014","unstructured":"Carta M, Tronci E (2014) Serotonin system implication in l-DOPA-induced dyskinesia: from animal models to clinical investigations. Front Neurol 5:78. https:\/\/doi.org\/10.3389\/fneur.2014.00078","journal-title":"Front Neurol"},{"issue":"Pt 7","key":"7316_CR16","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1093\/brain\/awm082","volume":"130","author":"M Carta","year":"2007","unstructured":"Carta M, Carlsson T, Kirik D, Bjorklund A (2007) Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130(Pt 7):1819\u20131833. https:\/\/doi.org\/10.1093\/brain\/awm082","journal-title":"Brain"},{"key":"7316_CR17","doi-asserted-by":"publisher","first-page":"242","DOI":"10.3389\/fneur.2014.00242","volume":"5","author":"MA Cenci","year":"2014","unstructured":"Cenci MA (2014) Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications. Front Neurol 5:242. https:\/\/doi.org\/10.3389\/fneur.2014.00242","journal-title":"Front Neurol"},{"key":"7316_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cells13060511","author":"J Cohen","year":"2024","unstructured":"Cohen J, Mathew A, Dourvetakis KD, Sanchez-Guerrero E, Pangeni RP, Gurusamy N et al (2024) Recent research trends in neuroinflammatory and neurodegenerative disorders. Cells. https:\/\/doi.org\/10.3390\/cells13060511","journal-title":"Cells"},{"issue":"9","key":"7316_CR19","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/0028-3908(87)90110-9","volume":"26","author":"FC Colpaert","year":"1987","unstructured":"Colpaert FC (1987) Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 26(9):1431\u20131440. https:\/\/doi.org\/10.1016\/0028-3908(87)90110-9","journal-title":"Neuropharmacology"},{"key":"7316_CR20","doi-asserted-by":"publisher","first-page":"923957","DOI":"10.3389\/fnins.2022.923957","volume":"16","author":"DMG Cunha","year":"2022","unstructured":"Cunha DMG, Becegato M, Meurer YSR, Lima AC, Goncalves N, Bioni VS et al (2022) Neuroinflammation in early, late and recovery stages in a progressive parkinsonism model in rats. Front Neurosci 16:923957. https:\/\/doi.org\/10.3389\/fnins.2022.923957","journal-title":"Front Neurosci"},{"issue":"2","key":"7316_CR21","doi-asserted-by":"publisher","first-page":"196","DOI":"10.2174\/0118715249260445231226112021","volume":"24","author":"AC Custodio-Silva","year":"2024","unstructured":"Custodio-Silva AC, Beserra-Filho JIA, Soares-Silva B, Maria-Macedo A, Silva-Martins S, Silva SP et al (2024) Purple carrot extract exhibits a neuroprotective profile in th e nigrostriatal pathway in the reserpine-induced model of Parkinson \u2018s Disease. Cent Nerv Syst Agents Med Chem 24(2):196\u2013205. https:\/\/doi.org\/10.2174\/0118715249260445231226112021","journal-title":"Cent Nerv Syst Agents Med Chem"},{"issue":"6","key":"7316_CR22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5(6):525\u2013535. https:\/\/doi.org\/10.1016\/S1474-4422(06)70471-9","journal-title":"Lancet Neurol"},{"key":"7316_CR23","doi-asserted-by":"publisher","first-page":"114722","DOI":"10.1016\/j.physbeh.2024.114722","volume":"288","author":"TFO Dos Santos","year":"2025","unstructured":"Dos Santos TFO, Melo JEC, Santos HF, Souza JLS, Santos ER, de Oliveira MCS et al (2025) Repeated balance exercise promotes cholinergic neuroprotection of the pedunculopontine nucleus in a progressive model of Parkinson\u2019s disease. Physiol Behav 288:114722. https:\/\/doi.org\/10.1016\/j.physbeh.2024.114722","journal-title":"Physiol Behav"},{"issue":"4","key":"7316_CR24","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","volume":"164","author":"S Duty","year":"2011","unstructured":"Duty S, Jenner P (2011) Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164(4):1357\u20131391. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01426.x","journal-title":"Br J Pharmacol"},{"issue":"5","key":"7316_CR25","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00213-023-06350-6","volume":"240","author":"GP Fadanni","year":"2023","unstructured":"Fadanni GP, Leao A, Granzotto N, Pereira AG, de Gois AM, Anjos PAR et al (2023) Genetic effects in a progressive model of parkinsonism induced by reserpine. Psychopharmacology 240(5):1131\u20131142. https:\/\/doi.org\/10.1007\/s00213-023-06350-6","journal-title":"Psychopharmacology"},{"key":"7316_CR26","doi-asserted-by":"publisher","first-page":"112934","DOI":"10.1016\/j.physbeh.2020.112934","volume":"222","author":"HM Fahmy","year":"2020","unstructured":"Fahmy HM, Khadrawy YA, Abd-El Daim TM, Elfeky AS, Abd Rabo AA, Mustafa AB et al (2020) Thymoquinone-encapsulated chitosan nanoparticles coated with polysorbate 80 as a novel treatment agent in a reserpine-induced depression animal model. Physiol Behav 222:112934. https:\/\/doi.org\/10.1016\/j.physbeh.2020.112934","journal-title":"Physiol Behav"},{"issue":"7","key":"7316_CR27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.neuropharm.2005.01.014","volume":"48","author":"RR Faria","year":"2005","unstructured":"Faria RR, Abilio VC, Grassl C, Chinen CC, Negrao LT, de Castro JP et al (2005) Beneficial effects of vitamin C and vitamin E on reserpine-induced oral dyskinesia in rats: critical role of striatal catalase activity. Neuropharmacology 48(7):993\u20131001. https:\/\/doi.org\/10.1016\/j.neuropharm.2005.01.014","journal-title":"Neuropharmacology"},{"issue":"Pt 5","key":"7316_CR28","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1093\/brain\/114.5.2283","volume":"114","author":"JM Fearnley","year":"1991","unstructured":"Fearnley JM, Lees AJ (1991) Ageing and Parkinson\u2019s disease: substantia Nigra regional selectivity. Brain 114(Pt 5):2283\u20132301. https:\/\/doi.org\/10.1093\/brain\/114.5.2283","journal-title":"Brain"},{"issue":"1","key":"7316_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbr.2012.03.008","volume":"231","author":"VS Fernandes","year":"2012","unstructured":"Fernandes VS, Santos JR, Leao AH, Medeiros AM, Melo TG, Izidio GS et al (2012) Repeated treatment with a low dose of reserpine as a progressive model of Parkinson\u2019s disease. Behav Brain Res 231(1):154\u2013163. https:\/\/doi.org\/10.1016\/j.bbr.2012.03.008","journal-title":"Behav Brain Res"},{"issue":"1","key":"7316_CR30","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0014-2999(75)90154-5","volume":"33","author":"JM Goldstein","year":"1975","unstructured":"Goldstein JM, Barnett A, Malick JB (1975) The evaluation of anti-Parkinson drugs on reserpine-induced rigidity in rats. Eur J Pharmacol 33(1):183\u2013188. https:\/\/doi.org\/10.1016\/0014-2999(75)90154-5","journal-title":"Eur J Pharmacol"},{"key":"7316_CR31","doi-asserted-by":"publisher","first-page":"177655","DOI":"10.1016\/j.ejphar.2025.177655","volume":"998","author":"A Gomez-Paz","year":"2025","unstructured":"Gomez-Paz A, Calderon V, Luna-Leal A, Palomero-Rivero M, Bargas J (2025) A positive allosteric modulator of \u03b17 nicotinic receptor reduces levodopa-induced dyskinesias in hemi-parkinsonian mice. Eur J Pharmacol 998:177655. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177655","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"7316_CR32","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/ana.22423","volume":"69","author":"MD Gottwald","year":"2011","unstructured":"Gottwald MD, Aminoff MJ (2011) Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Ann Neurol 69(6):919\u2013927. https:\/\/doi.org\/10.1002\/ana.22423","journal-title":"Ann Neurol"},{"issue":"12","key":"7316_CR33","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s004150050530","volume":"246","author":"F Grandas","year":"1999","unstructured":"Grandas F, Galiano ML, Tabernero C (1999) Risk factors for levodopa-induced dyskinesias in Parkinson\u2019s disease. J Neurol 246(12):1127\u20131133. https:\/\/doi.org\/10.1007\/s004150050530","journal-title":"J Neurol"},{"issue":"1","key":"7316_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000215875","volume":"62","author":"RA Hauser","year":"2009","unstructured":"Hauser RA (2009) Levodopa: past, present, and future. Eur Neurol 62(1):1\u20138. https:\/\/doi.org\/10.1159\/000215875","journal-title":"Eur Neurol"},{"issue":"1","key":"7316_CR35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1046\/j.1471-4159.1995.65010192.x","volume":"65","author":"MJ Heeringa","year":"1995","unstructured":"Heeringa MJ, Abercrombie ED (1995) Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. J Neurochem 65(1):192\u2013200. https:\/\/doi.org\/10.1046\/j.1471-4159.1995.65010192.x","journal-title":"J Neurochem"},{"key":"7316_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3389\/fnins.2015.00503","volume":"9","author":"SA Jagmag","year":"2015","unstructured":"Jagmag SA, Tripathi N, Shukla SD, Maiti S, Khurana S (2015) Evaluation of models of Parkinson\u2019s disease. Front Neurosci 9:503. https:\/\/doi.org\/10.3389\/fnins.2015.00503","journal-title":"Front Neurosci"},{"issue":"4","key":"7316_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2147\/ndt.s2006","volume":"4","author":"J Jankovic","year":"2008","unstructured":"Jankovic J, Aguilar LG (2008) Current approaches to the treatment of Parkinson\u2019s disease. Neuropsychiatr Dis Treat 4(4):743\u2013757. https:\/\/doi.org\/10.2147\/ndt.s2006","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"Suppl","key":"7316_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1136\/jnnp.52.suppl.22","volume":"52","author":"P Jenner","year":"1989","unstructured":"Jenner P (1989) Clues to the mechanism underlying dopamine cell death in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 52(Suppl):22\u201328. https:\/\/doi.org\/10.1136\/jnnp.52.suppl.22","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"7316_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1006\/neur.1995.0016","volume":"4","author":"BS Jeon","year":"1995","unstructured":"Jeon BS, Jackson-Lewis V, Burke RE (1995) 6-Hydroxydopamine lesion of the rat substantia nigra: time course and morphology of cell death. Neurodegeneration 4(2):131\u2013137. https:\/\/doi.org\/10.1006\/neur.1995.0016","journal-title":"Neurodegeneration"},{"issue":"9996","key":"7316_CR40","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386(9996):896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3","journal-title":"Lancet"},{"issue":"1\u20132","key":"7316_CR41","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jns.2014.03.028","volume":"340","author":"EA Kozina","year":"2014","unstructured":"Kozina EA, Khakimova GR, Khaindrava VG, Kucheryanu VG, Vorobyeva NE, Krasnov AN et al (2014) Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism. J Neurol Sci 340(1\u20132):198\u2013207. https:\/\/doi.org\/10.1016\/j.jns.2014.03.028","journal-title":"J Neurol Sci"},{"issue":"1-2","key":"7316_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/0304-3940(94)90957-1","volume":"179","author":"GJ LaHoste","year":"1994","unstructured":"LaHoste GJ, Marshall JF (1994) Rapid development of D1 and D2 dopamine receptor supersensitivity as indicated by striatal and pallidal Fos expression. Neurosci Lett 179(1\u20132):153\u2013156. https:\/\/doi.org\/10.1016\/0304-3940(94)90957-1","journal-title":"Neurosci Lett"},{"issue":"3","key":"7316_CR43","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/ejn.14119","volume":"49","author":"EL Lane","year":"2019","unstructured":"Lane EL (2019) L-DOPA for Parkinson\u2019s disease-a bittersweet pill. Eur J Neurosci 49(3):384\u2013398. https:\/\/doi.org\/10.1111\/ejn.14119","journal-title":"Eur J Neurosci"},{"key":"7316_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3389\/fnins.2016.00283","volume":"10","author":"PC Leal","year":"2016","unstructured":"Leal PC, Lins LC, de Gois AM, Marchioro M, Santos JR (2016) Commentary: Evaluation of models of Parkinson\u2019s disease. Front Neurosci 10:283. https:\/\/doi.org\/10.3389\/fnins.2016.00283","journal-title":"Front Neurosci"},{"issue":"4","key":"7316_CR45","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/bpa.12253","volume":"25","author":"AH Leao","year":"2015","unstructured":"Leao AH, Sarmento-Silva AJ, Santos JR, Ribeiro AM, Silva RH (2015) Molecular, neurochemical, and behavioral hallmarks of reserpine as a model for Parkinson\u2019s disease: new perspectives to a long-standing model. Brain Pathol 25(4):377\u2013390. https:\/\/doi.org\/10.1111\/bpa.12253","journal-title":"Brain Pathol"},{"key":"7316_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3389\/fnagi.2017.00078","volume":"9","author":"AH Leao","year":"2017","unstructured":"Leao AH, Meurer YS, da Silva AF, Medeiros AM, Campelo CL, Abilio VC et al (2017) Spontaneously hypertensive rats (SHR) are resistant to a reserpine-induced progressive model of Parkinson\u2019s disease: Differences in motor behavior, tyrosine hydroxylase and alpha-synuclein expression. Front Aging Neurosci 9:78. https:\/\/doi.org\/10.3389\/fnagi.2017.00078","journal-title":"Front Aging Neurosci"},{"key":"7316_CR47","doi-asserted-by":"publisher","first-page":"113349","DOI":"10.1016\/j.bbr.2021.113349","volume":"410","author":"AHFF Leao","year":"2021","unstructured":"Leao AHFF, Meurer YSR, Freitas TA, Medeiros AM, Abilio VC, Izidio GS et al (2021) Changes in the mesocorticolimbic pathway after low dose reserpine-treatment in Wistar and Spontaneously Hypertensive Rats (SHR): implications for cognitive deficits in a progressive animal model for Parkinson\u2019s disease. Behav Brain Res 410:113349. https:\/\/doi.org\/10.1016\/j.bbr.2021.113349","journal-title":"Behav Brain Res"},{"key":"7316_CR48","doi-asserted-by":"publisher","first-page":"757714","DOI":"10.3389\/fnagi.2021.757714","volume":"13","author":"AC Lima","year":"2021","unstructured":"Lima AC, Meurer YSR, Bioni VS, Cunha DMG, Goncalves N, Lopes-Silva LB et al (2021) Female rats are resistant to cognitive, motor and dopaminergic deficits in the reserpine-induced progressive model of Parkinson\u2019s disease. Front Aging Neurosci 13:757714. https:\/\/doi.org\/10.3389\/fnagi.2021.757714","journal-title":"Front Aging Neurosci"},{"key":"7316_CR49","doi-asserted-by":"publisher","first-page":"1539783","DOI":"10.3389\/fphar.2025.1539783","volume":"16","author":"AC Lima","year":"2025","unstructured":"Lima AC, Bioni VS, Becegato MS, Meier Y, Cunha DMG, Aguiar NA et al (2025) Preventive beneficial effects of cannabidiol in a reserpine-induced progressive model of parkinsonism. Front Pharmacol 16:1539783. https:\/\/doi.org\/10.3389\/fphar.2025.1539783","journal-title":"Front Pharmacol"},{"key":"7316_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.brainresbull.2018.01.017","volume":"139","author":"LCRF Lins","year":"2018","unstructured":"Lins LCRF, Souza MF, Bispo JMM, Gois AM, Melo TCS, Andrade RAS et al (2018) Carvacrol prevents impairments in motor and neurochemical parameters in a model of progressive parkinsonism induced by reserpine. Brain Res Bull 139:9\u201315. https:\/\/doi.org\/10.1016\/j.brainresbull.2018.01.017","journal-title":"Brain Res Bull"},{"key":"7316_CR51","doi-asserted-by":"publisher","first-page":"1463941","DOI":"10.3389\/fncir.2024.1463941","volume":"18","author":"N Lipari","year":"2024","unstructured":"Lipari N, Galfano A, Venkatesh S, Grezenko H, Sandoval IM, Manfredsson FP et al (2024) The effects of chemogenetic targeting of serotonin-projecting pathways on L-DOPA-induced dyskinesia and psychosis in a bilateral rat model of Parkinson\u2019s disease. Front Neural Circuits 18:1463941. https:\/\/doi.org\/10.3389\/fncir.2024.1463941","journal-title":"Front Neural Circuits"},{"key":"7316_CR52","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X251380196","author":"H Liu","year":"2025","unstructured":"Liu H, Wang R, Xu Y, Dai W, Wang P (2025) Buspirone regulates cortico-striatal gamma oscillations to ameliorate dyskinesia. J Parkinsons Dis. https:\/\/doi.org\/10.1177\/1877718X251380196","journal-title":"J Parkinsons Dis"},{"key":"7316_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s00221-024-06811-0","author":"LB Lopes-Silva","year":"2024","unstructured":"Lopes-Silva LB, Cunha DMG, Lima AC, Bioni VS, Goncalves N, Kurita JPF et al (2024) Sleep deprivation induces late deleterious effects in a pharmacological model of parkinsonism. Exp Brain Res. https:\/\/doi.org\/10.1007\/s00221-024-06811-0","journal-title":"Exp Brain Res"},{"key":"7316_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.bbr.2014.02.039","volume":"266","author":"Y Ma","year":"2014","unstructured":"Ma Y, Zhan M, OuYang L, Li Y, Chen S, Wu J et al (2014) The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats. Behav Brain Res 266:37\u201345. https:\/\/doi.org\/10.1016\/j.bbr.2014.02.039","journal-title":"Behav Brain Res"},{"key":"7316_CR55","doi-asserted-by":"publisher","first-page":"1664269","DOI":"10.3389\/fnagi.2025.1664269","volume":"17","author":"VFB Macedo","year":"2025","unstructured":"Macedo VFB, Macedo VKB, de Miranda Coelho JAP, de MeloBarboza AM (2025) Parkinson\u2019s disease physiopathology-beyond the. Front Aging Neurosci 17:1664269. https:\/\/doi.org\/10.3389\/fnagi.2025.1664269","journal-title":"Front Aging Neurosci"},{"key":"7316_CR56","doi-asserted-by":"publisher","first-page":"102162","DOI":"10.1016\/j.jchemneu.2022.102162","volume":"125","author":"JEC Melo","year":"2022","unstructured":"Melo JEC, Santos TFO, Santos RS, Franco HS, Monteiro MCN, Bispo JMM et al (2022) Aging accentuates decrease in tyrosine hydroxylase immunoreactivity associated with the increase in the motor impairment in a model of reserpine-induced parkinsonism. J Chem Neuroanat 125:102162. https:\/\/doi.org\/10.1016\/j.jchemneu.2022.102162","journal-title":"J Chem Neuroanat"},{"key":"7316_CR57","doi-asserted-by":"publisher","first-page":"1720571","DOI":"10.3389\/fneur.2025.1720571","volume":"16","author":"SO Mittal","year":"2025","unstructured":"Mittal SO, Krystkowiak P, Ramberg CJ, Sarathchandran P, Hassan A, Iantorno V et al (2025) Faith, fasting, and well-being: Emirates Neurology Society consensus guidelines on safe Ramadan fasting in Parkinson\u2019s disease. Front Neurol 16:1720571. https:\/\/doi.org\/10.3389\/fneur.2025.1720571","journal-title":"Front Neurol"},{"issue":"1","key":"7316_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/BF02244874","volume":"116","author":"JL Neisewander","year":"1994","unstructured":"Neisewander JL, Castaneda E, Davis DA (1994) Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia. Psychopharmacology 116(1):79\u201384. https:\/\/doi.org\/10.1007\/BF02244874","journal-title":"Psychopharmacology"},{"issue":"3","key":"7316_CR59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.neulet.2008.07.039","volume":"443","author":"AP Nicholas","year":"2008","unstructured":"Nicholas AP, Buck K, Ferger B (2008) Effects of levodopa on striatal monoamines in mice with levodopa-induced hyperactivity. Neurosci Lett 443(3):204\u2013208. https:\/\/doi.org\/10.1016\/j.neulet.2008.07.039","journal-title":"Neurosci Lett"},{"issue":"12","key":"7316_CR60","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00702-003-0047-1","volume":"110","author":"E Obuchowicz","year":"2003","unstructured":"Obuchowicz E, Antkiewicz-Michaluk L, Romanska I, Herman ZS (2003) Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice. J Neural Transm (Vienna) 110(12):1375\u20131391. https:\/\/doi.org\/10.1007\/s00702-003-0047-1","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"7316_CR61","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.36922\/an.4037","volume":"3","author":"LFM Olivatto","year":"2024","unstructured":"Olivatto LFM, Cunha DMG, Silva LB, Lima AC, Becegato M, Bioni VS et al (2024) Unpredictable mild stress accelerates the emergence of motor deficits in a rat model of progressive parkinsonism. Adv Neurol 3(4):4037. https:\/\/doi.org\/10.36922\/an.4037","journal-title":"Adv Neurol"},{"issue":"1","key":"7316_CR62","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.neuropharm.2011.08.039","volume":"62","author":"RD Prediger","year":"2012","unstructured":"Prediger RD, Matheus FC, Schwarzbold ML, Lima MM, Vital MA (2012) Anxiety in Parkinson\u2019s disease: a critical review of experimental and clinical studies. Neuropharmacology 62(1):115\u2013124. https:\/\/doi.org\/10.1016\/j.neuropharm.2011.08.039","journal-title":"Neuropharmacology"},{"issue":"1","key":"7316_CR63","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0091-3057(95)00164-6","volume":"53","author":"J Salamone","year":"1996","unstructured":"Salamone J, Baskin P (1996) Vacuous jaw movements induced by acute reserpine and low-dose apomorphine: possible model of Parkinsonian tremor. Pharmacol Biochem Behav 53(1):179\u2013183. https:\/\/doi.org\/10.1016\/0091-3057(95)00164-6","journal-title":"Pharmacol Biochem Behav"},{"issue":"6","key":"7316_CR64","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/s0301-0082(98)00053-7","volume":"56","author":"JD Salamone","year":"1998","unstructured":"Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998) Tremulous jaw movements in rats: a model of Parkinsonian tremor. Prog Neurobiol 56(6):591\u2013611. https:\/\/doi.org\/10.1016\/s0301-0082(98)00053-7","journal-title":"Prog Neurobiol"},{"key":"7316_CR65","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.bbr.2013.06.031","volume":"253","author":"JR Santos","year":"2013","unstructured":"Santos JR, Cunha JA, Dierschnabel AL, Campelo CL, Leao AH, Silva AF et al (2013) Cognitive, motor and tyrosine hydroxylase temporal impairment in a model of parkinsonism induced by reserpine. Behav Brain Res 253:68\u201377. https:\/\/doi.org\/10.1016\/j.bbr.2013.06.031","journal-title":"Behav Brain Res"},{"issue":"1 Pt B","key":"7316_CR66","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.tiv.2015.11.004","volume":"30","author":"NA Santos","year":"2015","unstructured":"Santos NA, Martins NM, Sisti FM, Fernandes LS, Ferreira RS, Queiroz RH et al (2015) The neuroprotection of cannabidiol against MPP(+)-induced toxicity in PC12 cells involves trkA receptors, upregulation of axonal and synaptic proteins, neuritogenesis, and might be relevant to Parkinson\u2019s disease. Toxicol in Vitro 30(1 Pt B):231\u2013240. https:\/\/doi.org\/10.1016\/j.tiv.2015.11.004","journal-title":"Toxicol in Vitro"},{"key":"7316_CR67","doi-asserted-by":"publisher","DOI":"10.4172\/2167-0501.1000153","author":"A Sarmento-Silva","year":"2014","unstructured":"Sarmento-Silva A, Lima R, Cabral A, Meurer Y, Ribeiro A, Silva RJBP (2014) Alpha-tocopherol counteracts cognitive and motor deficits induced by repeated treatment with reserpine. Biochem Pharmacol (Los Angel). https:\/\/doi.org\/10.4172\/2167-0501.1000153","journal-title":"Biochem Pharmacol (Los Angel)"},{"key":"7316_CR68","doi-asserted-by":"publisher","first-page":"140445","DOI":"10.1016\/j.ijbiomac.2025.140445","volume":"301","author":"R Shen","year":"2025","unstructured":"Shen R, Wang J, Zhao Y, Dang Z, Zhang K, Li M et al (2025) Polysaccharides from Scrophularia ningpoensis Hemsl. improve reserpine-induced depression-like behavior by inhibiting HTR2A\/HTR2C mediated AKT\/GSK3\u03b2\/\u03b2-catenin\/CBP\/BDNF signalling. Int J Biol Macromol 301:140445. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.140445","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"7316_CR69","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0166-4328(01)00409-0","volume":"132","author":"RH Silva","year":"2002","unstructured":"Silva RH, Abilio VC, Torres-Leite D, Bergamo M, Chinen CC, Claro FT et al (2002) Concomitant development of oral dyskinesia and memory deficits in reserpine-treated male and female mice. Behav Brain Res 132(2):171\u2013177. https:\/\/doi.org\/10.1016\/s0166-4328(01)00409-0","journal-title":"Behav Brain Res"},{"key":"7316_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14020156","author":"RH Silva","year":"2024","unstructured":"Silva RH, Lopes-Silva LB, Cunha DG, Becegato M, Ribeiro AM, Santos JR (2024) Animal approaches to studying risk factors for Parkinson\u2019s disease: a narrative review. Brain Sci. https:\/\/doi.org\/10.3390\/brainsci14020156","journal-title":"Brain Sci"},{"issue":"11","key":"7316_CR71","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1111\/1440-1681.13563","volume":"48","author":"S Silva-Martins","year":"2021","unstructured":"Silva-Martins S, Beserra-Filho JIA, Maria-Macedo A, Custodio-Silva AC, Soares-Silva B, Silva SP et al (2021) Myrtenol complexed with \u03b2\u2010cyclodextrin ameliorates behavioural deficits and reduces oxidative stress in the reserpine\u2010induced animal model of parkinsonism. Clin Exp Pharmacol Physiol 48(11):1488\u20131499. https:\/\/doi.org\/10.1111\/1440-1681.13563","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"11","key":"7316_CR72","doi-asserted-by":"publisher","first-page":"267","DOI":"10.4236\/jbbs.2021.1111022","volume":"11","author":"MB Soares","year":"2021","unstructured":"Soares MB, Lopes-Silva LB, Becegato M, Bioni VS, Lima AC, Ferreira GM et al (2021) Reserpine-induced progressive parkinsonism in mice predisposed and non-predisposed to depressive-like behavior. J Behav Brain Sci 11(11):267\u2013279","journal-title":"J Behav Brain Sci"},{"issue":"1","key":"7316_CR73","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/toxics3010075","volume":"3","author":"BJ Stansley","year":"2015","unstructured":"Stansley BJ, Yamamoto BK (2015) L-Dopa and brain serotonin system dysfunction. Toxics 3(1):75\u201388. https:\/\/doi.org\/10.3390\/toxics3010075","journal-title":"Toxics"},{"key":"7316_CR74","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","volume":"106-107","author":"SR Subramaniam","year":"2013","unstructured":"Subramaniam SR, Chesselet MF (2013) Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease. Prog Neurobiol 106\u2013107:17\u201332. https:\/\/doi.org\/10.1016\/j.pneurobio.2013.04.004","journal-title":"Prog Neurobiol"},{"key":"7316_CR75","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.nbd.2013.08.014","volume":"60","author":"E Tronci","year":"2013","unstructured":"Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P et al (2013) 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson\u2019s disease model. Neurobiol Dis 60:108\u2013114. https:\/\/doi.org\/10.1016\/j.nbd.2013.08.014","journal-title":"Neurobiol Dis"},{"key":"7316_CR76","doi-asserted-by":"publisher","first-page":"115497","DOI":"10.1016\/j.expneurol.2025.115497","volume":"395","author":"S Venkatesh","year":"2025","unstructured":"Venkatesh S, Kinzonzi N, Galfano A, Shah A, Franks J, Holden H et al (2025) Optimizing L-DOPA treatment through treadmill controlled exercise in a hemi-parkinsonian rat model. Exp Neurol 395:115497. https:\/\/doi.org\/10.1016\/j.expneurol.2025.115497","journal-title":"Exp Neurol"},{"issue":"Pt 2","key":"7316_CR77","doi-asserted-by":"publisher","first-page":"117303","DOI":"10.1016\/j.bcp.2025.117303","volume":"242","author":"J Wang","year":"2025","unstructured":"Wang J, Qiao Z, Cao X, Li H, Wang Y, Jiao Q et al (2025) G protein-coupled receptors: key targets for maintaining the function of basal ganglia-thalamus-cortical circuits in Parkinson\u2019s disease. Biochem Pharmacol 242(Pt 2):117303. https:\/\/doi.org\/10.1016\/j.bcp.2025.117303","journal-title":"Biochem Pharmacol"},{"key":"7316_CR78","first-page":"3","volume-title":"Behavioural models in psychopharmacology: theoretical, industrial and clinical perspectives","author":"P Willner","year":"1991","unstructured":"Willner P (1991) Behavioural models in psychopharmacology. Behavioural models in psychopharmacology: theoretical, industrial and clinical perspectives. Cambridge University Press, New York, pp 3\u201318"},{"issue":"Suppl 1","key":"7316_CR79","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10654-011-9581-6","volume":"26","author":"K Wirdefeldt","year":"2011","unstructured":"Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson\u2019s disease: a review of the evidence. Eur J Epidemiol 26(Suppl 1):S1-58. https:\/\/doi.org\/10.1007\/s10654-011-9581-6","journal-title":"Eur J Epidemiol"}],"container-title":["Experimental Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00221-026-07316-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00221-026-07316-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00221-026-07316-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:05:12Z","timestamp":1780664712000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00221-026-07316-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":79,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["7316"],"URL":"https:\/\/doi.org\/10.1007\/s00221-026-07316-8","relation":{},"ISSN":["0014-4819","1432-1106"],"issn-type":[{"value":"0014-4819","type":"print"},{"value":"1432-1106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"115"}}